PATENT CLAIM ANALYSIS

Application Number: 16128419
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-03
Patent Classification: ["514", "272000"]

Abstract:
The disclosure provides methods for the treatment of Friedreich's ataxia (FRDA), an autosomal recessive ataxia caused by mutation of the FXN gene, by administering to a subject a therapeutically effective amount of etravirine, or a pharmaceutically acceptable salt thereof. Etravirine is demonstrated to increase the levels of frataxin precursor and intermediate and mature forms of frataxin.

Claim (Index 16):
The method of  claim 1 , wherein the method comprises administering to the subject two 50 mg to 150 mg tablets comprising etravirine twice daily and wherein the subject is over 18 years of age and.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 97.0
- Lexical Diversity: 1.33333
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14862072', '15472852', '13820092', '14034224', '15568961']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7703687721569267
- 35 USC 102 Novelty (BERT): 0.5299057396136759
- Combined Prediction Score: 0.7463224689026017
- Mean Citation Score: 331.807922
- Max Citation Score: 344.77557
- Similarity Product: 190.62265758429768

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test